Two perspectives: medication derived from private research and medications derived from public research should be regulated in two manners. FIRST: private research derivatives should be priced at a return on investment and a reasonable profit basis which encourages additional drug research or improvements in modifying that drug. Private research is essential, yet because the drugs affect life and survival improvements we should permit generous rewards, but not abusive rewards. Any medication derived from public funding should be released into public domain to be owned by United States citizens. Of course, the FDA MUST REGULATE DRUG SAFETY AND SIDE EFFECTS of ALL medications.